TTOO Stock - T2 Biosystems, Inc.
Unlock GoAI Insights for TTOO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $7.19M | $22.30M | $28.06M | $18.13M | $8.34M |
| Gross Profit | $-8,170,000 | $1.17M | $7.36M | $-3,150,000 | $-8,428,000 |
| Gross Margin | -113.6% | 5.2% | 26.2% | -17.4% | -101.1% |
| Operating Income | $-49,664,000 | $-54,045,000 | $-42,973,000 | $-41,356,000 | $-52,058,000 |
| Net Income | $-50,077,000 | $-62,003,000 | $-49,241,000 | $-46,798,000 | $-59,006,000 |
| Net Margin | -696.2% | -278.0% | -175.5% | -258.1% | -707.9% |
| EPS | $-19.19 | $-1222.14 | $-1549.82 | $-1928.54 | $-6934.20 |
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance to identify carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Visit WebsiteEarnings History & Surprises
TTOOEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Oct 6, 2025 | — | — | — | — |
Q3 2025 | Aug 1, 2025 | — | — | — | — |
Q2 2025 | May 29, 2025 | — | — | — | — |
Q1 2025 | Mar 28, 2025 | — | — | — | — |
Q4 2024 | Nov 14, 2024 | $-0.64 | $-0.57 | +10.9% | ✓ BEAT |
Q3 2024 | Jul 29, 2024 | $-0.97 | $-0.66 | +32.0% | ✓ BEAT |
Q2 2024 | May 6, 2024 | $-1.86 | $-2.66 | -43.0% | ✗ MISS |
Q1 2024 | Mar 20, 2024 | $-3.85 | $-3.45 | +10.4% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-3.85 | $-3.45 | +10.4% | ✓ BEAT |
Q3 2023 | Aug 7, 2023 | $-0.27 | $-8.00 | -2863.0% | ✗ MISS |
Q2 2023 | May 23, 2023 | $-1.20 | $-117.00 | -9650.0% | ✗ MISS |
Q1 2023 | Mar 13, 2023 | $-1.70 | $-1.41 | +17.1% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-2.04 | $-295.00 | -14360.8% | ✗ MISS |
Q3 2022 | Aug 15, 2022 | $-4.50 | $-500.00 | -11011.1% | ✗ MISS |
Q2 2022 | May 5, 2022 | $-3.50 | $-500.00 | -14185.7% | ✗ MISS |
Q1 2022 | Feb 17, 2022 | $-4.50 | $-350.00 | -7677.8% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-4.00 | $-400.00 | -9900.0% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-400.00 | $-400.00 | 0.0% | = MET |
Q2 2021 | May 6, 2021 | $-350.00 | $-350.00 | 0.0% | = MET |
Q1 2021 | Mar 4, 2021 | $-300.00 | $-350.00 | -16.7% | ✗ MISS |
Latest News
Frequently Asked Questions about TTOO
What is TTOO's current stock price?
What is the analyst price target for TTOO?
What sector is T2 Biosystems, Inc. in?
What is TTOO's market cap?
Does TTOO pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to TTOO for comparison